Regarding combinational therapy, a clinical trial is currently testing the PD-1 monoclonal antibody termed pembrolizumab in patients with stage IV K-RAS mutant NSCLC in combination with trametinib (ClinicalTrials.gov identifier: NCT03299088). This evidence concerns the gene KRAS and non-small cell lung carcinoma.